• 1
    Clemente, C. G., Mihm, M. C. Jr., Bufalino, R., Zurrida, S., Collini, P. and Cascinelli, N., Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996. 77: 13031310.
  • 2
    Taylor, R. C., Patel, A., Panageas, K. S., Busam, K. J. and Brady, M. S., Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J. Clin. Oncol. 2007. 25: 869875.
  • 3
    Pages, F., Berger, A., Camus, M., Sanchez-Cabo, F., Costes, A., Molidor, R., Mlecnik, B. et al., Effector memory T cells, early metastasis, and survival in colorectal cancer. N. Engl. J. Med. 2005. 353: 26542666.
  • 4
    Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pages, C., Tosolini, M. et al., Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006. 313: 19601964.
  • 5
    Piersma, S. J., Jordanova, E. S., van Poelgeest, M. I., Kwappenberg, K. M., van der Hulst, J. M., Drijfhout, J. W., Melief, C. J. et al., High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res. 2007. 67: 354361.
  • 6
    Gao, Q., Qiu, S. J., Fan, J., Zhou, J., Wang, X. Y., Xiao, Y. S., Xu, Y. et al., Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J. Clin. Oncol. 2007. 25: 25862593.
  • 7
    Lee, H. E., Chae, S. W., Lee, Y. J., Kim, M. A., Lee, H. S., Lee, B. L. and Kim, W. H., Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer. Br. J. Cancer. 2008. 99: 17041711.
  • 8
    Sharma, P., Shen, Y., Wen, S., Yamada, S., Jungbluth, A. A., Gnjatic, S., Bajorin, D. F. et al., CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc. Natl. Acad. Sci. USA 2007. 104: 39673972.
  • 9
    Buckanovich, R. J., Facciabene, A., Kim, S., Benencia, F., Sasaroli, D., Balint, K., Katsaros, D. et al., Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat. Med. 2008. 14: 2836.
  • 10
    Jain, R. K., Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005. 307: 5862.
  • 11
    Manzur, M., Hamzah, J. and Ganss, R., Modulation of the “blood-tumor” barrier improves immunotherapy. Cell Cycle 2008. 7: 24522455.
  • 12
    Hamzah, J., Jugold, M., Kiessling, F., Rigby, P., Manzur, M., Marti, H. H., Rabie, T. et al., Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 2008. 453: 410414.
  • 13
    Sakaguchi, S., Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat. Immunol. 2005. 6: 345352.
  • 14
    Kim, J. Y., Kim, H. J., Hurt, E. M., Chen, X., Howard, O. M. and Farrar, W. L., Functional and genomic analyses of FOXP3-transduced Jurkat-T cells as regulatory T (Treg)-like cells. Biochem. Biophys. Res. Commun. 2007. 362: 4450.
  • 15
    Wan, S., Xia, C. and Morel, L., IL-6 produced by dendritic cells from lupus-prone mice inhibits CD4+CD25+ T cell regulatory functions. J. Immunol. 2007. 178: 271279.
  • 16
    Woo, E. Y., Chu, C. S., Goletz, T. J., Schlienger, K., Yeh, H., Coukos, G., Rubin, S. C. et al., Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 2001. 61: 47664772.
  • 17
    Liyanage, U. K., Moore, T. T., Joo, H. G., Tanaka, Y., Herrmann, V., Doherty, G., Drebin, J. A. et al., Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 2002. 169: 27562761.
  • 18
    Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M. et al., Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 2004. 10: 942949.
  • 19
    Hiraoka, N., Onozato, K., Kosuge, T. and Hirohashi, S., Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin. Cancer Res. 2006. 12: 54235434.
  • 20
    Zou, W., Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 2006. 6: 295307.
  • 21
    Valzasina, B., Piconese, S., Guiducci, C. and Colombo, M. P., Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25- lymphocytes is thymus and proliferation independent. Cancer Res. 2006. 66: 44884495.
  • 22
    Zhou, G. and Levitsky, H. I., Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance. J. Immunol. 2007. 178: 21552162.
  • 23
    Liu, V. C., Wong, L. Y., Jang, T., Shah, A. H., Park, I., Yang, X., Zhang, Q. et al., Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta. J. Immunol. 2007. 178: 28832892.
  • 24
    North, R. J., Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J. Exp. Med. 1982. 155: 10631074.
  • 25
    Matsushita, N., Pilon-Thomas, S. A., Martin, L. M. and Riker, A. I., Comparative methodologies of regulatory T cell depletion in a murine melanoma model. J. Immunol. Methods 2008. 333: 167179.
  • 26
    Sutmuller, R. P., van Duivenvoorde, L. M., van Elsas, A., Schumacher, T. N., Wildenberg, M. E., Allison, J. P., Toes, R. E. et al., Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 2001. 194: 823832.
  • 27
    Tanaka, H., Tanaka, J., Kjaergaard, J. and Shu, S., Depletion of CD4+ CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes. J. Immunother. 2002. 25: 207217.
  • 28
    Onizuka, S., Tawara, I., Shimizu, J., Sakaguchi, S., Fujita, T. and Nakayama, E., Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res. 1999. 59: 31283133.
  • 29
    Quezada, S. A., Peggs, K. S., Simpson, T. R., Shen, Y., Littman, D. R. and Allison, J. P., Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J. Exp. Med. 2008. 205: 21252138.
  • 30
    Pilon-Thomas, S., Mackay, A., Vohra, N. and Mule, J. J., Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma. J. Immunol. 2010. 184: 34423449.
  • 31
    Suffner, J., Hochweller, K., Kuhnle, M. C., Li, X., Kroczek, R. A., Garbi, N. and Hammerling, G. J., Dendritic cells support homeostatic expansion of Foxp3+ regulatory T cells in Foxp3.LuciDTR mice. J. Immunol. 2010. 184: 18101820.
  • 32
    Ganss, R., Ryschich, E., Klar, E., Arnold, B. and Hammerling, G. J., Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res. 2002. 62: 14621470.
  • 33
    Garbi, N., Arnold, B., Gordon, S., Hammerling, G. J. and Ganss, R., CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction. J. Immunol. 2004. 172: 58615869.
  • 34
    Thompson, E. D., Enriquez, H. L., Fu, Y. X. and Engelhard, V. H., Tumor masses support naive T cell infiltration, activation, and differentiation into effectors. J. Exp. Med. 2010. 207: 17911804.
  • 35
    Cao, Y., Zhao, J., Yang, Z., Cai, Z., Zhang, B., Zhou, Y., Shen, G. X. et al., CD4+FOXP3+ regulatory T cell depletion by low-dose cyclophosphamide prevents recurrence in patients with large condylomata acuminata after laser therapy. Clin. Immunol. 2010. 136: 2129.
  • 36
    Powell, D. J., Jr., Attia, P., Ghetie, V., Schindler, J., Vitetta, E. S. and Rosenberg, S. A., Partial reduction of human FOXP3+ CD4 T cells in vivo after CD25-directed recombinant immunotoxin administration. J. Immunother. 2008. 31: 189198.
  • 37
    Morse, M. A., Hobeika, A. C., Osada, T., Serra, D., Niedzwiecki, D., Lyerly, H. K. and Clay, T. M., Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 2008. 112: 610618.
  • 38
    Dannull, J., Su, Z., Rizzieri, D., Yang, B. K., Coleman, D., Yancey, D., Zhang, A. et al., Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest. 2005. 115: 36233633.
  • 39
    Mahnke, K., Schonfeld, K., Fondel, S., Ring, S., Karakhanova, S., Wiedemeyer, K., Bedke, T. et al., Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int. J. Cancer 2007. 120: 27232733.
  • 40
    Bielekova, B., Howard, T., Packer, A. N., Richert, N., Blevins, G., Ohayon, J., Waldmann, T. A. et al., Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch. Neurol. 2009. 66: 483489.
  • 41
    Rose, J. W., Burns, J. B., Bjorklund, J., Klein, J., Watt, H. E. and Carlson, N. G., Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology 2007. 69: 785789.
  • 42
    Waldmann, T. A., Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey. J. Clin. Immunol. 2007. 27: 118.
  • 43
    Wiseman, L. R. and Faulds, D., Daclizumab: a review of its use in the prevention of acute rejection in renal transplant recipients. Drugs 1999. 58: 10291042.
  • 44
    Gonzalez, E., Gutierrez, E., Hernandez, Y., Rosello, G., Gutierrez, M. J., Martinez, E. G., Manzanera, M. J. et al., Anti-CD25 monoclonal antibody sequential immunosuppressive induction therapy in renal transplants with high risk of delayed graft function. Transplant Proc. 2005. 37: 37363737.
  • 45
    Rech, A. J. and Vonderheide, R. H., Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann. NY Acad. Sci. 2009. 1174: 99106.
  • 46
    Tomayko, M. M. and Reynolds, C. P., Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother. Pharmacol. 1989. 24: 148154.
  • 47
    Miloud, T., Henrich, C. and Hammerling, G. J., Quantitative comparison of click beetle and firefly luciferases for in vivo bioluminescence imaging. J. Biomed. Opt. 2007. 12: 054018.